¿Eres un paciente de mieloma múltiple?
En MyGSK encontrarás información de interés como consejos de nutrición además de obtener un apoyo individualizado y acceso directo a la Comunidad Española de Pacientes con Mieloma Múltiple (CEMMp).
¿Quieres saber más?
Entra y regístrate con el código de acceso PACMIELOMA.

Pacientes ficticios, únicamente con fines ilustrativos
Diagnóstico del Mieloma Múltiple

CPs: células plasmáticas
MM: mieloma múltiple
GMSI: gammapatía monoclonal de significado incierto
RM: resonancia magnética
Referencias:
- National Comprehensive Cancer Network (NCCN). NCCN Guidelines for Patients: Multiple Myeloma, 2019 [Internet]. Plymouth Meeting (PA): NCCN, 2019 [acceso Marzo 2022]. Disponible en: https://www.nccn.org/patients/guidelines/content/PDF/myeloma-patient.pdf
- Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91(7):719-34.
- Rajkumar SV. Multiple Myeloma: 2020 update on Diagnosis, Risk-stratification and Management. Am J Hematol. 2020;95(5):548-67.
- Koshiaris C, Oke J, Abel L, Nicholson BD, Ramasamy K, Van den Bruel A. Quantifying intervals to diagnosis in myeloma: a systematic review and meta-analysis. BMJ open. 2018;8(6):e019758-e.
- Howell DA, Smith AG, Jack A, Patmore R, Macleod U, Mironska E, et al. Time-to-diagnosis and symptoms of myeloma, lymphomas and leukaemias: a report from the Haematological Malignancy Research Network. BMC Hematol. 2013;13(1):9.
- Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046.
- Fundación contra el cáncer (FCC), Serie de Guías Para Pacientes ESMO/FCC, ¿Qué es el mieloma múltiple? [Internet], European Society for Medical Oncology (ESMO), 2017 [acceso Marzo 2022]. Disponible en: https://www.esmo.org/content/download/138236/2546627/1
- Graziani G, Herget GW, Ihorst G, Zeissig M, Chaidos A, Auner HW, et al. Time from first symptom onset to the final diagnosis of multiple myeloma (MM) - possible risks and future solutions: retrospective and prospective «Deutsche Studiengruppe MM» (DSMM) and «European Myeloma Network» (EMN) analysis. Leuk Lymphoma. 2020;61(4):875-86.
- Howell DA, Smith AG, Jack A, Patmore R, Macleod U, Mironska E, et al. Time-to-diagnosis and symptoms of myeloma, lymphomas and leukaemias: a report from the Haematological Malignancy Research Network. BMC Hematol. 2013;13(1):9.
- Kunacheewa C, Orlowski RZ. New Drugs in Multiple Myeloma. Annu Rev Med. 2019;70:521-47.
- Asonitis N, Angelousi A, Zafeiris C, Lambrou GI, Dontas I, Kassi E. Diagnosis, Pathophysiology and Management of Hypercalcemia in Malignancy: A Review of the Literature. Horm Metab Res. 2019;51(12):770-8.
- Bouchnita A, Eymard N, Moyo TK, Koury MJ, Volpert V. Bone marrow infiltration by multiple myeloma causes anemia by reversible disruption of erythropoiesis. Am J Hematol. 2016;91(4):371-8.
- Hameed A, Brady JJ, Dowling P, Clynes M, O'Gorman P. Bone disease in multiple myeloma: pathophysiology and management. Cancer Growth Metastasis. 2014;7:33-42.
- Khouri J, Samaras C, Valent J, Mejia Garcia A, Faiman B, Mathur S, et al. Monoclonal gammopathy of undetermined significance: A primary care guide. Cleve Clin J Med. 2019;86(1):39-46.
- Go RS, Rajkumar SV. How I manage monoclonal gammopathy of undetermined significance. Blood. 2018;131(2):163-73.
- Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for multiple myeloma: A report from international myeloma working group. J Clin Oncol. 2015;33(26):2863-9.
- Lehners N, Becker N, Benner A, Pritsch M, Löpprich M, Mai EK, et al. Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response. Cancer Med. 2018;7(2):307-16.
- Chakraborty R, Majhail NS. Treatment and disease-related complications in multiple myeloma: Implications for survivorship. Am J Hematol. 2020;95(6):672-690.
- Carreras E. GUÍA DEL TRASPLANTE DE MÉDULA ÓSEA PARA EL PACIENTE [Internet]. Fundación Josep Carreras contra la leucemia, 2016 [acceso Marzo 2022]. Disponible en: https://www.fcarreras.org/es/guiatrasplante
- Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28 Suppl 4:iv52-iv61.
- Asociación de pacientes de Linfoma, Mieloma, Leucemia y Síndromes Mieloproliferativos (AEAL). El sitio de información del cáncer oncolohematológico para los pacientes [internet]. Mieloma España, 2017 [acceso Marzo 2022]. Disponible en: http://www.aeal.es/mieloma-multiple-espana/
- Moreau P, Attal M, Facon T. Frontline therapy of multiple myeloma. Blood. 2015;125(20):3076-84.
- Fonseca R, Abouzaid S, Bonafede M, Cai Q, Parikh K, Cosler L, et al. Trends in overall survival and costs of multiple myeloma, 2000-2014. Leukemia. 2017;31(9):1915-21.
- Lehners N, Becker N, Benner A, Pritsch M, Löpprich M, Mai EK, et al. Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response. Cancer Med. 2018;7(2):307-16.
- Rajkumar SV. Multiple myeloma: Every year a new standard? Hematol Oncol. 2019;37 Suppl 1(Suppl 1):62-5.
- Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, et al. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia. 2018;32(2):252-62.
- Kurtin S. Relapsed or Relapsed/Refractory Multiple Myeloma. J Adv Pract Oncol. 2013;4(6 (suppl 1)):5-14.
- Verelst SGR, Blommestein HM, De Groot S, Gonzalez-McQuire S, DeCosta L, de Raad JB, et al. Long-term Outcomes in Patients With Multiple Myeloma: A Retrospective Analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS). Hemasphere. 2018;2(4):e45.